107902-67-0Relevant academic research and scientific papers
Substrate specificity of the kinetic resolution of sulfides by enantioselective sulfoxide formation
Phillips, Michael L.,Panetta, Jill A.
, p. 2109 - 2114 (1997)
The kinetic resolution of tazofelone (1) has been reported. The resolution of this sulfide was accomplished via enantioselective sulfoxide formation with tert-Bu hydroperoxide in the presence of a chiral tartrate/titanium complex. The resolution was performed on analogues of compound 1 in order to explore the substrate specificity of the kinetic resolution, These experiments have shown that the success of the enantioselective oxidation of this sulfide by tert-Bu hydroperoxide is greatly influenced by the nature of the neighboring amide functionality.
Synthesis of 4-Thiazolidinones From Rhodanines by Thiocarbonyl Removal
Hansen, Marvin M.,Harkness, Allen R.
, p. 6971 - 6974 (1994)
A new procedure for synthesis of 4-thiazolidinones from readily available rhodanines is reported.Slow addition of the substrate to excess zinc dust in acetic acid at reflux affords the best yields.Identification of dimeric byproducts led to development of
A novel protecting group for hindered phenols
Hansen, Marvin M.,Riggs, Jennifer R.
, p. 2705 - 2706 (1998)
Boc2O and DMAP were used to protect hindered phenols as their Boc derivatives under mild conditions. Deprotection conditions were developed to suppress loss of a tert-butyl group from the aromatic ring, or alkylation of an additional tert-butyl group at an unsubstituted ortho or para position.
The development of a manufacturable synthesis of LY213829
Slattery, Brian J.,Kjell, Douglas P.,Copp, James D.,Ginah, Francis O.,Hansen, Marvin M.,Stirm, Stephen C.
, p. 295 - 297 (2013/09/07)
The development of a manufacturable synthesis of LY213829 (4-thiazolidinone-5-[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl] methyl) is described. Rather than reduction to eliminate the thiocarbonyl from the rhodanine moiety, the new route utilizes a novel
Alternate crystal form of Tazofelone
-
, (2008/06/13)
PCT No. PCT/US96/14132 Sec. 371 Date Feb. 25, 1998 Sec. 102(e) Date Feb. 25, 1998 PCT Filed Sep. 3, 1996 PCT Pub. No. WO97/09320 PCT Pub. Date Mar. 13, 1997The instant invention provides novel crystalline Form II of (+/-)-5-{[3,5-bis(1,1dimethylethyl)-4-hydroxyphenyl]methyl}-4-thiazolidinone having an x-ray powder diffraction patter with specific d spacings useful for treating inflammation, inflammatory bowel disease, allergies, arthritis and hypoglycemia utilizing the novel physical form as well as pharmaceutical compositions containing the same. A process for preparing Form II Tazofelone is described.
Process for preparing benzyl-substituted rhodanine derivatives
-
, (2008/06/13)
The instant invention provides a novel process for preparing benzyl-substituted rhodanine derivatives. Also provided are novel benzyl-substituted thiolamides and benzyl-substituted hemithioacetals. Such compounds are useful as intermediates in preparing t
Product structure as a function of reaction conditions in the reaction of formaldehyde with an alpha-mercapto amide
Copp, James D.,Ginah, Francis O.,Hansen, Marvin M.,Kjell, Douglas P.,Slattery, Brian J.
, p. 1307 - 1312 (2007/10/03)
Treatment of mercapto amide (3) with formaldehyde and acid or base results in products whose structures are a function of the reaction conditions. Lactone (8), hemithioacetal (9), and dimer (7) were formed in good yields under acidic reaction conditions.
Method for treating multiple sclerosis
-
, (2008/06/13)
Provided is a method of treating multiple sclerosis employing certain aryl-substituted rhodanines.
Process for preparing benzyl-substituted rhodanine derivatives
-
, (2008/06/13)
The instant invention provides a novel process for preparing benzyl-substituted rhodanine derivatives. The process is particularly useful for synthesizing the enantiomers of such derivatives. Also provided are novel benzyl-substituted mercaptopropanoic ac
Aryl-substituted rhodanine derivatives
-
, (2008/06/13)
Provided are certain aryl-substituted rhodanine derivatives, treatment methods and pharmaceutical formulations thereof.
